Novo Nordisk’s shock decision to oust its chief executive has resulted in the Ozempic maker once again becoming Europe’s ...

It’s the hot-shot fix that took Hollywood — and now high school — by storm. Ozempic and other so-called “miracle” weight-loss ...

Key Takeaways Novo Nordisk stock rose on Tuesday after the Financial Times reported that an activist investor is building a ...

Positive news from the laboratory was the wind beneath the wings of Novo Nordisk (NYSE: NVO) stock on Thursday. The ...

As more people resort to a new generation of drugs to achieve the perfect body, Leah Hardy examines the latest warnings over ...

Novo Nordisk’s drugs are being linked to an eye condition that can cause vision loss, while health tech companies made CNBC’s ...

Activist hedge fund Parvus Asset Management is building a stake in Ozempic -maker Novo Nordisk as the drugmaker hunts for a ...

Novo Nordisk's GLP-1 agonist semaglutide, used to treat diabetes and obesity, may cause a serious eye condition that can lead ...

Deep Apple is the latest biotech to be tapped by Novo Nordisk as the drugmaker aims to regain market share lost to Eli Lilly.

Novo Nordisk is progressing both subcutaneous and oral versions of amycretin into Phase III trials for patients with obesity ...

Women employed at Novo Nordisk A/S are now paid more on average than the men working at the maker of blockbuster drugs Wegovy ...

The European Medicines Agency has indicated that Novo Nordisk's drugs, Ozempic and Wegovy, may rarely cause a serious eye ...